



**Attn: Trading and Market Making/Legal and
Compliance/Operations/Systems**

UNIFORM PRACTICE ADVISORY (UPC # 019-09) June 19, 2009

**XTL Biopharmaceuticals Ltd – American Depositary Receipts (OTC:
XTLBY)**

Concurrent with a 1-5 Reverse Stock Split of the ordinary shares of XTL Biopharmaceuticals Ltd, the outstanding ADR (XTLBY) has undergone a ratio change from 1 ADR representing 10 ordinary shares (1:10) to 1 ADR representing 2 ordinary shares (1:2).

The ratio change will be effective June 22, 2009 and should not result in a price adjustment to XTLBY.

Questions regarding the split of the ordinary shares should be directed to the Agent: Bank of New York.

Questions regarding this notice should be directed to: FINRA
Operations: 1-866-776-0800